Sanofi (SNY): what the price assumes

In the published model solve dated 2026-Q2, anchored at $42.79, Sanofi (SNY) is priced for -2.6% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/SNY

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.4% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.8pp.

Reconcile: at the x-ray's 9.3% required return this reads ~9.4%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.3%); the inversion above states its own rate.

Per-Model Detail (n=18)

Solvency

Bullet Takeaways

• Sanofi is priced for decline while growing double digits: the quote implies roughly negative 2.6 percent annual operating growth, yet first-quarter 2026 sales rose 13.6 percent at constant exchange rates with Dupixent up 30.8 percent to €4,170 million across nine indications.
• The defining risk is concentration on a clock: Dupixent's compound patent runs to 2031, the lifecycle-extension pillars are still in clinical development, and the launch portfolio at €1,171 million per quarter remains roughly a quarter of Dupixent's output.
• Watch the second-quarter report in late July 2026 against affirmed guidance of high single-digit constant-currency sales growth, plus second-half 2026 clinical starts for the monthly Dupixent co-formulation and phase III progression of amlitelimab and lunsekimig.

Bull Case

The bear owns the first paragraph: Sanofi is a one-engine story, that engine's compound patent expires in 2031, and everyone knows it. Dupixent generated €4,170 million in the first quarter alone, up 30.8 percent, which makes it both the growth franchise and the concentration risk in a single line item. Now test that fear against the price. At about 15 times operating income, today's $43.49 implies operating growth of roughly negative 2.6 percent a year for the next five years. The market is not pricing the patent cliff as a 2031 problem; it is pricing Sanofi as if the decline had already started. Against that assumption, the company just grew net sales 13.6 percent at constant exchange rates with business EPS, its company-defined measure, up 14.0 percent. A stock priced for shrinkage that is growing double digits is the cheapest kind of disagreement to own.

The growth is broader than the headline drug. Pharma launches grew 49.6 percent to €1,171 million in the quarter, the pipeline delivered positive phase II data for lunsekimig in asthma and nasal polyps and for amlitelimab in atopic dermatitis, and management laid out a three-pillar Dupixent lifecycle defense: a monthly-dosing co-formulation entering clinical studies in the second half of 2026, high-dose asthma development, and new alliance assets. The vaccines arm added Heplisav-B and a shingles candidate through the closed $2.2 billion Dynavax acquisition. None of these individually replaces Dupixent; collectively they are exactly how large pharma franchises get extended, indication by indication, formulation by formulation.

The financial structure removes the usual excuses. Net debt of $7.5 billion is a fraction of a year's operating income, interest coverage runs near 10 times, the share count edges down as the company works through a €1 billion buyback that was €921 million complete at the first quarter, and 2026 guidance calls for high single-digit sales growth at constant exchange rates with business EPS growing slightly faster. Every family of valuation method, asset, earnings power, peer multiples, and forward growth, lands at or above today's price, a pattern that rarely accompanies genuine deterioration. The bull case is simply that the market's implied decline never shows up on schedule.

Bear Case

The price leans on a chain of assumptions, so name them in order of fragility. First and heaviest: that Dupixent keeps compounding until its 2031 compound patent expiry and that the lifecycle defense holds afterward. The first quarter's 30.8 percent Dupixent growth to €4,170 million benefited from what management itself flagged as a low comparison base, and the three-pillar extension strategy, monthly co-formulation, high-dose asthma, alliance assets, is a plan announced precisely because the base case without it is erosion. Biologic franchises at this scale attract biosimilar and competitive entry the way Humira did, and AbbVie's own filings document how quickly a dominant immunology franchise's pricing degrades once loyalty economics shift, with even adjacent brands like Botox Cosmetic showing double-digit US declines on pricing dynamics (accession 0001551152-26-000008). Sanofi's answer to the cliff is execution that has not happened yet.

Second: that the launch portfolio scales fast enough to matter. Pharma launches grew 49.6 percent but to just €1,171 million, roughly a quarter of Dupixent's single-quarter output. The gap between the engine and its replacements is measured in years of flawless execution, through phase III readouts (amlitelimab and lunsekimig are phase II stories so far), regulatory reviews, and payer negotiations in a US market where drug-pricing policy pressure is structural rather than cyclical. Vaccines, the other pillar, is a business Sanofi is buying growth for via Dynavax at $2.2 billion, which is what companies do when organic franchises mature.

Third, the discount itself may be the market being right. All four valuation families sit at or near this price, which means the bear case is not overvaluation, it is that Sanofi deserves its multiple: a mature European pharma with one outsized asset, a payer environment tightening in its largest market, currency translation noise between the euro business and the ADR, and a pipeline whose winners are years from replacing what the patent office will eventually take away. The implied negative growth in the price is not an anomaly to arbitrage; it is the base rate for big pharma revenue bases post-cliff. If Dupixent's growth normalizes before the launches scale, the stock does not need to fall to disappoint; it just needs to sit still while the story ages.

Valuation

Start with the unusual pattern: every family of valuation method reaches this price. Asset-based reads sit essentially at the quote, earnings power within a few percent, peer multiples about 10 percent above it, and the forward-growth methods at par. When all four lenses agree, the market is not paying a premium to any of them, and the disagreement that usually drives a valuation section collapses into a single question of trajectory. The inversion sharpens it: at $43.49 (July 10, 2026), roughly 15 times operating income, the price implies operating growth of about negative 2.6 percent a year over five years at a 7.5 percent cost of capital. The market is pricing modest decline from a company that just reported 13.6 percent constant-currency sales growth.

The composition of that growth is what a buyer is really weighing. Dupixent, at €4,170 million for the quarter and up 30.8 percent across nine indications, carries the top line; pharma launches contributed €1,171 million growing 49.6 percent; and 2026 guidance calls for high single-digit constant-currency sales growth with business EPS, the company's non-GAAP measure, growing slightly faster. Against an implied negative growth path, even partial delivery of that guidance out-earns the price's assumption. The offsetting weight is concentration: the growth engine's compound patent runs to 2031, and the extension strategy (monthly co-formulation, high-dose asthma, alliance assets) is in clinical development rather than on the market.

Solvency is a non-story in the best sense: net debt of $7.5 billion runs about a fifth of a year's operating income, interest coverage sits near 10 times, the company generates cash, and the share count declines slightly as the €1 billion buyback executes. The downside is therefore not financial but narrative: a value-supported price with no premium attached, whose main risk is that the implied decline eventually becomes the reality once the patent calendar catches up. What the buyer underwrites at 15 times is that the next five years look like the guidance, not like the inversion.

Catalysts

The April 23, 2026 first-quarter report beat on both lines: net sales of €10,509 million rose 13.6 percent at constant exchange rates, business EPS (the company's non-GAAP measure) reached €1.88, up 14.0 percent, and adjusted earnings of $1.10 per ADS topped the $1.06 consensus. Dupixent rose 30.8 percent to €4,170 million, helped by volume growth across nine indications and a low comparison base, while pharma launches grew 49.6 percent to €1,171 million. Full-year 2026 guidance was affirmed: high single-digit sales growth at constant exchange rates, with business EPS growing slightly faster than sales.

The pipeline calendar carries the multi-year story. Management unveiled a three-pillar strategy to extend Dupixent beyond its 2031 compound patent: a monthly (Q4W) dosing co-formulation entering clinical studies in the second half of 2026, high-dose asthma development, and new alliance assets. Phase II readouts already in hand include lunsekimig in asthma and chronic rhinosinusitis with nasal polyps and amlitelimab in atopic dermatitis with manageable safety; their phase III progression is the pipeline's proof burden over the next several quarters.

Capital deployment continues alongside: the $2.2 billion Dynavax acquisition closed, adding Heplisav-B and a shingles vaccine candidate to the vaccines franchise, and €921 million of the €1 billion share buyback was complete at the first-quarter mark. The next dated event is the second-quarter report expected in late July 2026, where the reads are Dupixent's growth rate against a normalizing base, launch-portfolio scaling, and any update to the US pricing and policy environment that most directly pressures the ADR's largest market.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• BMY (Bristol-Myers Squibb Company)
• FY2025 10-K: …in more efficient operations and putting us at a competitive disadvantage. These risks may result in an adverse impact on our business, financial condition or results of operations. 31 Strategic, Business Development and Employee Attraction and Retention Risks We depend on several key products for most of our…
• FY2025 10-K: …impacts its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the entity. Business Segment Information BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of…
• ABT (ABBOTT LABORATORIES)
• FY2025 10-K: 2024. In 2025, operating earnings for the Nutritional Products segment increased 3.5 percent compared to 2024. Operating margin profile for this segment increased from 16.4 percent in 2023 to 17.9 percent in 2024 and to 18.4 percent in 2025. The increase in 2025 primarily reflects the favorable effect of margin…
• FY2025 10-K: …Core Laboratory, Rapid Diagnostics, Molecular, and Point of Care businesses are aggregated and reported as the Diagnostic Products segment. Medical Devices -Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. For segment…
• GSK (GSK plc)
• FY2025 20-F: Notes to the financial statements continued 6. Turnover and segment information continued Net operating assets by segment 2025 £m 2024 £m Commercial Operations 13,286 12,501 Research and Development 9,637 7,459 Segment net operating assets 22,923 19,960 Corporate and other unallocated net operating assets 1,099 43 Net…
• FY2025 20-F: Group turnover by business Specialty Medicines (S) £13.5bn AER growth +14% CER growth +17% Vaccines (V) £9.2bn AER stable -% CER growth +2% General Medicines (G) £10.0bn AER decline -4% CER decline -1% S G V Group turnover by geographic region US Int US £16.9bn AER growth +3% CER growth +6% Europe £7.5bn AER growth…
• NVS (Novartis AG)
• FY2025 20-F: …growth drivers. • Embed operational excellence to deliver returns : In an increasingly competitive environment, we are simplifying processes and reducing costs to become more efficient and effective in our decision-making and to free up resources for investment in new medicines. Our goal is to continue making…
• FY2025 20-F: …behind priority brands and launches. Core operating income margin from continuing operations was 40.1% of net sales, increasing 1.4 percentage points (2.1 percentage points cc). Core net income was USD 17.4 billion (+11%, +12% cc), mainly due to higher core operating income. Core basic earnings per share was USD 8.98…
• AZN (ASTRAZENECA PLC)
• FY2025 20-F: …that there is not the clear link that exists in many manufacturing businesses between the revenue generated on an individual product sale and the associated cost and hence margin generated on a product. Consequently, the profitability of individual drugs or classes of drugs is not considered a key measure of…
• FY2025 20-F: …taken to limit healthcare spending may lead to lower than anticipated rates of growth in some markets and limit the incentives to develop innovative medicines resulting in an adverse impact on revenues and profitability. Any escalation in barriers to the global free flow of medicines could increase costs to serve…
• AMGN (Amgen Inc.)
• FY2025 10-K: …31, 2025, 2024 and 2023, we had product sales to three customers that individually accounted for more than 10% of total revenues. For the year ended December 31, 2025, on a combined basis, these customers accounted for 77 % of total gross revenues as shown in the following table. Certain information with respect to…
• FY2025 10-K: …can enhance such advantages. These advantages may make it difficult for us to compete with them successfully to discover, develop and market new products and for our current products to compete with new products or new product indications they may bring to market. As a result, our products have been competing and may…
• MDT (Medtronic plc)
• FY2025 10-K: …current environment of managed care, economically motivated 10 Table of Content customers, consolidation among healthcare providers, increased competition, declining reimbursement rates, and national and provincial tender pricing, competitively priced product offerings are essential to our business. In order to…
• FY2025 10-K: …operating profit in the budget and forecasting process and to monitor budget and forecast variances versus actual when assessing segment performance and allocating capital resources to each segment. The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be…
• ABBV (AbbVie Inc.)
• FY2025 10-K: …prior year. 41 | 2025 Form 10-K Net revenues for Botox Cosmetic decreased 4% in 2025. In the United States, Botox Cosmetic net revenues decreased 11% primarily driven by unfavorable pricing due to customer loyalty program changes, lower market share and decreased consumer demand, partially offset by the timing of…
• FY2025 10-K: …future periods. The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by CODM are reported on the consolidated statement of earnings for the years ended…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.